Le diagnostic se fait par des tests sanguins mesurant les niveaux de facteur IX.
Hémophilie BFacteur IXTests de coagulation
#2
Quels tests sont utilisés pour l'hémophilie B ?
Les tests incluent le temps de céphaline activé (TCA) et le dosage du facteur IX.
Hémophilie BTests de coagulationFacteur IX
#3
L'hérédité influence-t-elle le diagnostic ?
Oui, l'hémophilie B est souvent héréditaire, donc l'historique familial est important.
Hémophilie BHéréditéAntécédents familiaux
#4
Peut-on diagnostiquer l'hémophilie B à la naissance ?
Oui, des tests génétiques peuvent être effectués chez les nouveau-nés à risque.
Hémophilie BTests génétiquesNouveau-né
#5
Quels symptômes indiquent un test nécessaire ?
Des saignements fréquents ou prolongés après des blessures peuvent nécessiter un test.
Hémophilie BSaignementSymptômes
Symptômes
5
#1
Quels sont les symptômes courants de l'hémophilie B ?
Les symptômes incluent des saignements spontanés, des ecchymoses et des douleurs articulaires.
Hémophilie BSaignementEcchymoses
#2
Comment se manifestent les saignements ?
Les saignements peuvent être internes ou externes, souvent sans cause apparente.
Hémophilie BSaignementSaignement interne
#3
Les saignements articulaires sont-ils fréquents ?
Oui, les saignements dans les articulations, appelés hémarthroses, sont fréquents.
Hémophilie BHémarthroseSaignement
#4
Les symptômes varient-ils selon l'âge ?
Oui, les symptômes peuvent apparaître dès l'enfance ou plus tard selon la gravité.
Hémophilie BÂgeSymptômes
#5
Y a-t-il des signes d'alerte à surveiller ?
Des saignements inhabituels ou des ecchymoses sans raison doivent alerter.
Hémophilie BSaignementEcchymoses
Prévention
5
#1
Comment prévenir les saignements chez les hémophiles ?
Éviter les activités à risque et porter des protections peut aider à prévenir les saignements.
Hémophilie BPréventionActivités à risque
#2
Les vaccinations sont-elles importantes ?
Oui, les vaccinations sont cruciales pour prévenir les infections, surtout lors de traitements.
Hémophilie BVaccinationInfections
#3
Y a-t-il des conseils diététiques pour les hémophiles ?
Une alimentation équilibrée et riche en vitamine K peut soutenir la coagulation sanguine.
Hémophilie BNutritionVitamine K
#4
Les soins dentaires nécessitent-ils des précautions ?
Oui, des précautions doivent être prises pour éviter les saignements lors des soins dentaires.
Hémophilie BSoins dentairesSaignement
#5
Comment gérer les blessures mineures ?
Pour les blessures mineures, appliquer de la pression et utiliser des bandages est recommandé.
Hémophilie BBlessuresSoin des blessures
Traitements
5
#1
Quel est le traitement principal de l'hémophilie B ?
Le traitement principal est l'infusion de facteur IX pour prévenir ou traiter les saignements.
Hémophilie BFacteur IXTraitement
#2
Les traitements sont-ils préventifs ?
Oui, des traitements préventifs réguliers peuvent réduire le risque de saignements.
Hémophilie BPréventionTraitement préventif
#3
Y a-t-il des médicaments alternatifs ?
Des médicaments comme des agents hémostatiques peuvent être utilisés en complément.
Hémophilie BMédicamentsHémostatique
#4
Comment se déroule une infusion de facteur IX ?
L'infusion se fait par voie intraveineuse, souvent à domicile ou en milieu hospitalier.
Hémophilie BFacteur IXIntraveineuse
#5
Les traitements sont-ils coûteux ?
Oui, les traitements peuvent être coûteux, mais des aides financières existent.
Hémophilie BCoût des soinsAide financière
Complications
5
#1
Quelles sont les complications possibles de l'hémophilie B ?
Les complications incluent des hémorragies internes, des infections et des dommages articulaires.
Hémophilie BComplicationsHémorragie interne
#2
Les hémorragies peuvent-elles être mortelles ?
Oui, des hémorragies graves peuvent être mortelles si elles ne sont pas traitées rapidement.
Hémophilie BHémorragieUrgence médicale
#3
Comment les infections peuvent-elles survenir ?
Les infections peuvent survenir par transfusions de sang contaminé ou traitements non sécurisés.
Hémophilie BInfectionsTransfusions sanguines
#4
Les dommages articulaires sont-ils réversibles ?
Les dommages articulaires peuvent être permanents, nécessitant parfois une chirurgie corrective.
Hémophilie BDommages articulairesChirurgie
#5
Comment prévenir les complications ?
Un suivi médical régulier et un traitement approprié aident à prévenir les complications.
Hémophilie BPréventionSuivi médical
Facteurs de risque
5
#1
Quels sont les facteurs de risque de l'hémophilie B ?
Les facteurs de risque incluent des antécédents familiaux et des mutations génétiques spécifiques.
Hémophilie BFacteurs de risqueGénétique
#2
L'âge influence-t-il le risque d'hémophilie B ?
Non, l'hémophilie B est généralement présente à la naissance, indépendamment de l'âge.
Hémophilie BÂgeNaissance
#3
Les hommes sont-ils plus à risque ?
Oui, l'hémophilie B touche principalement les hommes en raison de son mode de transmission lié à l'X.
Hémophilie BSexeTransmission génétique
#4
Les mutations génétiques sont-elles fréquentes ?
Oui, des mutations dans le gène du facteur IX sont souvent responsables de l'hémophilie B.
Hémophilie BMutations génétiquesFacteur IX
#5
Les antécédents médicaux influencent-ils le risque ?
Les antécédents médicaux familiaux d'hémophilie augmentent le risque de développer la maladie.
Hémophilie BAntécédents médicauxHérédité
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Hémophilie B : Questions médicales les plus fréquentes",
"headline": "Hémophilie B : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Hémophilie B : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-23",
"dateModified": "2026-04-12",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Hémophilie B"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Maladies génétiques liées au chromosome X",
"url": "https://questionsmedicales.fr/mesh/D040181",
"about": {
"@type": "MedicalCondition",
"name": "Maladies génétiques liées au chromosome X",
"code": {
"@type": "MedicalCode",
"code": "D040181",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C16.320.322"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Hémophilie B",
"alternateName": "Hemophilia B",
"code": {
"@type": "MedicalCode",
"code": "D002836",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Giancarlo Castaman",
"url": "https://questionsmedicales.fr/author/Giancarlo%20Castaman",
"affiliation": {
"@type": "Organization",
"name": "Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy."
}
},
{
"@type": "Person",
"name": "Jan Astermark",
"url": "https://questionsmedicales.fr/author/Jan%20Astermark",
"affiliation": {
"@type": "Organization",
"name": "Center for Thrombosis and Haemostasis, Lund University, Skåne University Hospital, Malmö, Sweden."
}
},
{
"@type": "Person",
"name": "David L Cooper",
"url": "https://questionsmedicales.fr/author/David%20L%20Cooper",
"affiliation": {
"@type": "Organization",
"name": "Novo Nordisk Inc., Plainsboro, NJ, USA."
}
},
{
"@type": "Person",
"name": "Amy D Shapiro",
"url": "https://questionsmedicales.fr/author/Amy%20D%20Shapiro",
"affiliation": {
"@type": "Organization",
"name": "Indiana Hemophilia & Thrombosis Center, Indianapolis, IN."
}
},
{
"@type": "Person",
"name": "Frank W G Leebeek",
"url": "https://questionsmedicales.fr/author/Frank%20W%20G%20Leebeek",
"affiliation": {
"@type": "Organization",
"name": "From the Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor (S.W.P.); the Department of Hematology, Erasmus University Medical Center, University Medical Center Rotterdam, Rotterdam (F.W.G.L.), Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, Utrecht (P.V.V.), Vascular Medicine, Amsterdam University Medical Center, University of Amsterdam (M.C.), Amsterdam Cardiovascular Sciences, Pulmonary Hypertension and Thrombosis (M.C.), and uniQure Biopharma (Y.P.L.), Amsterdam, and University Medical Center Groningen, Groningen (K.M.) - all in the Netherlands; Yale University School of Medicine, New Haven, CT (M.R., S.L.); American Thrombosis and Hemostasis Network, Rochester, NY (M.R.); the Department of Medicine and UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill (N.S.K.); the Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy (G.C.); the Department of Hemostaseology and Hemophilia Center, Medical Clinic 2, Institute of Transfusion Medicine and Immunohematology, University Hospital Frankfurt, Frankfurt (W.M.), the Comprehensive Care Hemophilia Treatment Center, Vivantes Klinikum im Friedrichshain, Berlin, and the Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn (R. Klamroth) - all in Germany; the Department of Vascular Medicine and Hemostasis, Hemophilia Center, University Hospitals Leuven, Leuven (K.P.), the Division of Hematology, Cliniques Universitaires Saint-Luc, Brussels (C.R.J.R.H.), and Université Catholique de Louvain, Louvain-la-Neuve (C.R.J.R.H.) - all in Belgium; the Department of Hematology, Rigshopitalet Copenhagen, Copenhagen (P.K.); National Coagulation Centre, St. James's Hospital, Dublin (N.O.); Barts and the London School of Medicine and Dentistry, Queen Mary University of London (K.J.P., D.P.H.), and the Royal London Hospital Haemophilia Centre, Barts Health NHS Trust (D.P.H.), London, University Hospital Southampton and National Institute for Health and Care Research Clinical Research Facility, Southampton (R. Kazmi), and Cambridge University NHS Foundation Trust, Addenbrooks Hospital, Cambridge (E.S.) - all in the United Kingdom; the Department of Translational Medicine, Lund University, and the Department of Hematology Oncology and Radiation Physics, Skåne University Hospital - both in Malmö, Sweden (J.A.); the Department of Pediatrics, University of Utah, and Primary Children's Hospital, Salt Lake City (R.L.); University of South Florida, Tampa (N.V.); the Department of Medicine, Hemophilia and Thrombosis Treatment Center, San Diego (A.D.), the Cancer and Blood Disorders Institute, Children's Hospital Los Angeles (G.Y.), the Orthopaedic Hemophilia Treatment Center, the Luskin Orthopaedic Institute for Children (D.V.Q.), and the University of Southern California Keck School of Medicine (G.Y.), Los Angeles, and the Center for Inherited Blood Disorders, Orange (E.G.) - all in California; Arkansas Children's Hospital, Pulaski, and University of Arkansas for Medical Sciences, Little Rock (S.E.C.); University of Texas Health Science Center, McGovern Medical School, and Gulf States Hemophilia and Thrombophilia Center - both in Houston (M.E.); Washington Center for Bleeding Disorders and University of Washington, Seattle (R.K.-J.); Hemophilia and Thrombosis Center, University of Colorado Anschutz Medical Campus, Aurora (M.W.); the Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville (A.P.W.); uniQure, Lexington, MA (R.G., R.E.D., D.L.C.); and CSL Behring, King of Prussia, PA (Y.L., B.G., P.E.M.)."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Gene Therapy Approaches for the Treatment of Hemophilia B.",
"datePublished": "2023-06-28",
"url": "https://questionsmedicales.fr/article/37445943",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms241310766"
}
},
{
"@type": "ScholarlyArticle",
"name": "Bleeds and resource use in hemophilia B: retrospective observational study.",
"datePublished": "2024-05-01",
"url": "https://questionsmedicales.fr/article/38748916",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.37765/ajmc.2024.89543"
}
},
{
"@type": "ScholarlyArticle",
"name": "The frequency of complications in a cohort of patients diagnosed with hemophilia A and hemophilia B receiving prophylactic treatment in Colombia: A retrospective noninterventional study.",
"datePublished": "2023-11-27",
"url": "https://questionsmedicales.fr/article/38011251",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0286187"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pharmacokinetic model-based assessment of factor IX prophylaxis treatment regimens in severe hemophilia B.",
"datePublished": "2024-09-04",
"url": "https://questionsmedicales.fr/article/39227636",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-70784-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients.",
"datePublished": "2023-06-21",
"url": "https://questionsmedicales.fr/article/37341915",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12325-023-02570-6"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Malformations et maladies congénitales, héréditaires et néonatales",
"item": "https://questionsmedicales.fr/mesh/D009358"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies génétiques congénitales",
"item": "https://questionsmedicales.fr/mesh/D030342"
},
{
"@type": "ListItem",
"position": 4,
"name": "Maladies génétiques liées au chromosome X",
"item": "https://questionsmedicales.fr/mesh/D040181"
},
{
"@type": "ListItem",
"position": 5,
"name": "Hémophilie B",
"item": "https://questionsmedicales.fr/mesh/D002836"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Hémophilie B - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Hémophilie B",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-10",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Hémophilie B",
"description": "Comment diagnostiquer l'hémophilie B ?\nQuels tests sont utilisés pour l'hémophilie B ?\nL'hérédité influence-t-elle le diagnostic ?\nPeut-on diagnostiquer l'hémophilie B à la naissance ?\nQuels symptômes indiquent un test nécessaire ?",
"url": "https://questionsmedicales.fr/mesh/D002836#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Hémophilie B",
"description": "Quels sont les symptômes courants de l'hémophilie B ?\nComment se manifestent les saignements ?\nLes saignements articulaires sont-ils fréquents ?\nLes symptômes varient-ils selon l'âge ?\nY a-t-il des signes d'alerte à surveiller ?",
"url": "https://questionsmedicales.fr/mesh/D002836#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Hémophilie B",
"description": "Comment prévenir les saignements chez les hémophiles ?\nLes vaccinations sont-elles importantes ?\nY a-t-il des conseils diététiques pour les hémophiles ?\nLes soins dentaires nécessitent-ils des précautions ?\nComment gérer les blessures mineures ?",
"url": "https://questionsmedicales.fr/mesh/D002836#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Hémophilie B",
"description": "Quel est le traitement principal de l'hémophilie B ?\nLes traitements sont-ils préventifs ?\nY a-t-il des médicaments alternatifs ?\nComment se déroule une infusion de facteur IX ?\nLes traitements sont-ils coûteux ?",
"url": "https://questionsmedicales.fr/mesh/D002836#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Hémophilie B",
"description": "Quelles sont les complications possibles de l'hémophilie B ?\nLes hémorragies peuvent-elles être mortelles ?\nComment les infections peuvent-elles survenir ?\nLes dommages articulaires sont-ils réversibles ?\nComment prévenir les complications ?",
"url": "https://questionsmedicales.fr/mesh/D002836#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Hémophilie B",
"description": "Quels sont les facteurs de risque de l'hémophilie B ?\nL'âge influence-t-il le risque d'hémophilie B ?\nLes hommes sont-ils plus à risque ?\nLes mutations génétiques sont-elles fréquentes ?\nLes antécédents médicaux influencent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D002836#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer l'hémophilie B ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par des tests sanguins mesurant les niveaux de facteur IX."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour l'hémophilie B ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent le temps de céphaline activé (TCA) et le dosage du facteur IX."
}
},
{
"@type": "Question",
"name": "L'hérédité influence-t-elle le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'hémophilie B est souvent héréditaire, donc l'historique familial est important."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer l'hémophilie B à la naissance ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests génétiques peuvent être effectués chez les nouveau-nés à risque."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un test nécessaire ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des saignements fréquents ou prolongés après des blessures peuvent nécessiter un test."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants de l'hémophilie B ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des saignements spontanés, des ecchymoses et des douleurs articulaires."
}
},
{
"@type": "Question",
"name": "Comment se manifestent les saignements ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les saignements peuvent être internes ou externes, souvent sans cause apparente."
}
},
{
"@type": "Question",
"name": "Les saignements articulaires sont-ils fréquents ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les saignements dans les articulations, appelés hémarthroses, sont fréquents."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent apparaître dès l'enfance ou plus tard selon la gravité."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes d'alerte à surveiller ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des saignements inhabituels ou des ecchymoses sans raison doivent alerter."
}
},
{
"@type": "Question",
"name": "Comment prévenir les saignements chez les hémophiles ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les activités à risque et porter des protections peut aider à prévenir les saignements."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles importantes ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations sont cruciales pour prévenir les infections, surtout lors de traitements."
}
},
{
"@type": "Question",
"name": "Y a-t-il des conseils diététiques pour les hémophiles ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et riche en vitamine K peut soutenir la coagulation sanguine."
}
},
{
"@type": "Question",
"name": "Les soins dentaires nécessitent-ils des précautions ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des précautions doivent être prises pour éviter les saignements lors des soins dentaires."
}
},
{
"@type": "Question",
"name": "Comment gérer les blessures mineures ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pour les blessures mineures, appliquer de la pression et utiliser des bandages est recommandé."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal de l'hémophilie B ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal est l'infusion de facteur IX pour prévenir ou traiter les saignements."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils préventifs ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements préventifs réguliers peuvent réduire le risque de saignements."
}
},
{
"@type": "Question",
"name": "Y a-t-il des médicaments alternatifs ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme des agents hémostatiques peuvent être utilisés en complément."
}
},
{
"@type": "Question",
"name": "Comment se déroule une infusion de facteur IX ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'infusion se fait par voie intraveineuse, souvent à domicile ou en milieu hospitalier."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils coûteux ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être coûteux, mais des aides financières existent."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles de l'hémophilie B ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des hémorragies internes, des infections et des dommages articulaires."
}
},
{
"@type": "Question",
"name": "Les hémorragies peuvent-elles être mortelles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des hémorragies graves peuvent être mortelles si elles ne sont pas traitées rapidement."
}
},
{
"@type": "Question",
"name": "Comment les infections peuvent-elles survenir ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les infections peuvent survenir par transfusions de sang contaminé ou traitements non sécurisés."
}
},
{
"@type": "Question",
"name": "Les dommages articulaires sont-ils réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les dommages articulaires peuvent être permanents, nécessitant parfois une chirurgie corrective."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier et un traitement approprié aident à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque de l'hémophilie B ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque incluent des antécédents familiaux et des mutations génétiques spécifiques."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque d'hémophilie B ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'hémophilie B est généralement présente à la naissance, indépendamment de l'âge."
}
},
{
"@type": "Question",
"name": "Les hommes sont-ils plus à risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'hémophilie B touche principalement les hommes en raison de son mode de transmission lié à l'X."
}
},
{
"@type": "Question",
"name": "Les mutations génétiques sont-elles fréquentes ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations dans le gène du facteur IX sont souvent responsables de l'hémophilie B."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents médicaux familiaux d'hémophilie augmentent le risque de développer la maladie."
}
}
]
}
]
}
From the Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor (S.W.P.); the Department of Hematology, Erasmus University Medical Center, University Medical Center Rotterdam, Rotterdam (F.W.G.L.), Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, Utrecht (P.V.V.), Vascular Medicine, Amsterdam University Medical Center, University of Amsterdam (M.C.), Amsterdam Cardiovascular Sciences, Pulmonary Hypertension and Thrombosis (M.C.), and uniQure Biopharma (Y.P.L.), Amsterdam, and University Medical Center Groningen, Groningen (K.M.) - all in the Netherlands; Yale University School of Medicine, New Haven, CT (M.R., S.L.); American Thrombosis and Hemostasis Network, Rochester, NY (M.R.); the Department of Medicine and UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill (N.S.K.); the Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy (G.C.); the Department of Hemostaseology and Hemophilia Center, Medical Clinic 2, Institute of Transfusion Medicine and Immunohematology, University Hospital Frankfurt, Frankfurt (W.M.), the Comprehensive Care Hemophilia Treatment Center, Vivantes Klinikum im Friedrichshain, Berlin, and the Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn (R. Klamroth) - all in Germany; the Department of Vascular Medicine and Hemostasis, Hemophilia Center, University Hospitals Leuven, Leuven (K.P.), the Division of Hematology, Cliniques Universitaires Saint-Luc, Brussels (C.R.J.R.H.), and Université Catholique de Louvain, Louvain-la-Neuve (C.R.J.R.H.) - all in Belgium; the Department of Hematology, Rigshopitalet Copenhagen, Copenhagen (P.K.); National Coagulation Centre, St. James's Hospital, Dublin (N.O.); Barts and the London School of Medicine and Dentistry, Queen Mary University of London (K.J.P., D.P.H.), and the Royal London Hospital Haemophilia Centre, Barts Health NHS Trust (D.P.H.), London, University Hospital Southampton and National Institute for Health and Care Research Clinical Research Facility, Southampton (R. Kazmi), and Cambridge University NHS Foundation Trust, Addenbrooks Hospital, Cambridge (E.S.) - all in the United Kingdom; the Department of Translational Medicine, Lund University, and the Department of Hematology Oncology and Radiation Physics, Skåne University Hospital - both in Malmö, Sweden (J.A.); the Department of Pediatrics, University of Utah, and Primary Children's Hospital, Salt Lake City (R.L.); University of South Florida, Tampa (N.V.); the Department of Medicine, Hemophilia and Thrombosis Treatment Center, San Diego (A.D.), the Cancer and Blood Disorders Institute, Children's Hospital Los Angeles (G.Y.), the Orthopaedic Hemophilia Treatment Center, the Luskin Orthopaedic Institute for Children (D.V.Q.), and the University of Southern California Keck School of Medicine (G.Y.), Los Angeles, and the Center for Inherited Blood Disorders, Orange (E.G.) - all in California; Arkansas Children's Hospital, Pulaski, and University of Arkansas for Medical Sciences, Little Rock (S.E.C.); University of Texas Health Science Center, McGovern Medical School, and Gulf States Hemophilia and Thrombophilia Center - both in Houston (M.E.); Washington Center for Bleeding Disorders and University of Washington, Seattle (R.K.-J.); Hemophilia and Thrombosis Center, University of Colorado Anschutz Medical Campus, Aurora (M.W.); the Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville (A.P.W.); uniQure, Lexington, MA (R.G., R.E.D., D.L.C.); and CSL Behring, King of Prussia, PA (Y.L., B.G., P.E.M.).
From the Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor (S.W.P.); the Department of Hematology, Erasmus University Medical Center, University Medical Center Rotterdam, Rotterdam (F.W.G.L.), Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, Utrecht (P.V.V.), Vascular Medicine, Amsterdam University Medical Center, University of Amsterdam (M.C.), Amsterdam Cardiovascular Sciences, Pulmonary Hypertension and Thrombosis (M.C.), and uniQure Biopharma (Y.P.L.), Amsterdam, and University Medical Center Groningen, Groningen (K.M.) - all in the Netherlands; Yale University School of Medicine, New Haven, CT (M.R., S.L.); American Thrombosis and Hemostasis Network, Rochester, NY (M.R.); the Department of Medicine and UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill (N.S.K.); the Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy (G.C.); the Department of Hemostaseology and Hemophilia Center, Medical Clinic 2, Institute of Transfusion Medicine and Immunohematology, University Hospital Frankfurt, Frankfurt (W.M.), the Comprehensive Care Hemophilia Treatment Center, Vivantes Klinikum im Friedrichshain, Berlin, and the Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn (R. Klamroth) - all in Germany; the Department of Vascular Medicine and Hemostasis, Hemophilia Center, University Hospitals Leuven, Leuven (K.P.), the Division of Hematology, Cliniques Universitaires Saint-Luc, Brussels (C.R.J.R.H.), and Université Catholique de Louvain, Louvain-la-Neuve (C.R.J.R.H.) - all in Belgium; the Department of Hematology, Rigshopitalet Copenhagen, Copenhagen (P.K.); National Coagulation Centre, St. James's Hospital, Dublin (N.O.); Barts and the London School of Medicine and Dentistry, Queen Mary University of London (K.J.P., D.P.H.), and the Royal London Hospital Haemophilia Centre, Barts Health NHS Trust (D.P.H.), London, University Hospital Southampton and National Institute for Health and Care Research Clinical Research Facility, Southampton (R. Kazmi), and Cambridge University NHS Foundation Trust, Addenbrooks Hospital, Cambridge (E.S.) - all in the United Kingdom; the Department of Translational Medicine, Lund University, and the Department of Hematology Oncology and Radiation Physics, Skåne University Hospital - both in Malmö, Sweden (J.A.); the Department of Pediatrics, University of Utah, and Primary Children's Hospital, Salt Lake City (R.L.); University of South Florida, Tampa (N.V.); the Department of Medicine, Hemophilia and Thrombosis Treatment Center, San Diego (A.D.), the Cancer and Blood Disorders Institute, Children's Hospital Los Angeles (G.Y.), the Orthopaedic Hemophilia Treatment Center, the Luskin Orthopaedic Institute for Children (D.V.Q.), and the University of Southern California Keck School of Medicine (G.Y.), Los Angeles, and the Center for Inherited Blood Disorders, Orange (E.G.) - all in California; Arkansas Children's Hospital, Pulaski, and University of Arkansas for Medical Sciences, Little Rock (S.E.C.); University of Texas Health Science Center, McGovern Medical School, and Gulf States Hemophilia and Thrombophilia Center - both in Houston (M.E.); Washington Center for Bleeding Disorders and University of Washington, Seattle (R.K.-J.); Hemophilia and Thrombosis Center, University of Colorado Anschutz Medical Campus, Aurora (M.W.); the Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville (A.P.W.); uniQure, Lexington, MA (R.G., R.E.D., D.L.C.); and CSL Behring, King of Prussia, PA (Y.L., B.G., P.E.M.).
Gene Therapy Center, University of North Carolina, Chapel Hill, NC, USA. pablomonoloco@gmail.com.
Harold R. Roberts Comprehensive Hemophilia Diagnosis and Treatment Center, University of North Carolina, Chapel Hill, NC, USA. pablomonoloco@gmail.com.
Spark Therapeutics, Philadelphia, PA, USA. pablomonoloco@gmail.com.
In contrast to the standard enzyme-replacement therapy, administered from once per 7-14 days to 2-3 times a week in patients with severe hemophilia B, as a result of a single injection, gene therapy c...
To describe people with hemophilia B (PWHB) in the US who experience bleeds despite factor replacement therapy and to quantify the associated burden from the third-party payer perspective....
Observational study of adult male PWHB treated with factor IX replacement therapy identified from the PharMetrics Plus claims data from 2010 to 2019....
Patients with medically recorded bleeds (MRBs) were identified using diagnostic codes. Rates and rate ratios of inpatient admissions, emergency department (ED) visits, and outpatient visits among PWHB...
There were 345 PWHB with MRBs and 252 without MRBs. More than half of PWHB with MRBs (56.8%) had 1 or more comorbidity vs 39.3% of PWHB without MRBs. The prevalence of anxiety and depression was high ...
This study reports significant resource use and clinical burden among PWHB who seek medical care. PWHB with MRBs had considerable all-cause resource use compared with PWHB without MRBs. The prevalence...
Hemophilia A and B are disorders associated with the deficit of coagulation factors VIII and IX....
Was to determine the incidence of complications in a cohort of patients diagnosed with moderate and severe hemophilia A or B under treatment in a specialized institution....
A retrospective study of a cohort of patients with replacement therapy for hemophilia A or B, evaluating treatment and complications between January/2012 and July/2019. Sociodemographic, clinical and ...
A total of 159 male patients were identified with hemophilia A (n = 140; 88.1%) and B (n = 19; 11.9%) with a mean follow-up of 5.9±2.3 years. The mean age was 23.6±16.1 years, hemophilia was reported ...
The most common complication was joint bleeding which was expected in this type of patients. Low proportion of patients developed factor inhibitors during the follow up....
An important aspect of improving care for people with hemophilia B (HB) is developing optimal treatment strategies. Here we aimed to provide in-silico evidence, comparing the estimated optimal posolog...
Dalcinonacog alfa (DalcA), a novel subcutaneously administered recombinant human factor IX (FIX) variant is being developed for adult and paediatric patients with hemophilia B (HB). DalcA has been sho...
A population PK model was built using adult data from two clinical trials (NCT03186677, NCT03995784). With allometry in the model, clinical trial simulations were performed to study alternative dosing...
Almost 90% of the adults were predicted to achieve desirable FIX levels, i.e. 10% FIX activity, following daily 100 IU/kg dosing, with 90% of the subjects reaching target within 1.6-7.1 days. No every...
This study supported the adult dose selection for DalcA in the presence of sparse data and enabled first-in-paediatric dose selection to achieve FIX levels that reduce risk of spontaneous bleeds....
Gene therapy for hemophilia has been investigated for decades but no breakthroughs were made until Nathwani et al. achieved a significant and sustainable factor IX increase in hemophilia B patients in...
The introduction of adeno-associated virus-mediated, liver-directed gene therapy into the hemophilia treatment landscape brings not only great promise but also considerable uncertainty to a community ...
Arthropathy is a common complication in patients with hemophilia. We examined the prevalence of this skeletal complication in patients with hemophilia who were registered at a Comprehensive Hemophilia...
In this cross-sectional study, an orthopedic specialist visited 448 patients and conducted screenings for skeletal complications. The assessment included evaluating the type of hemophilia, disease sev...
Ninety patients with hemophilia A, with a mean age (SD) of 31.6 (14.4) years, and 10 patients with hemophilia B, with a mean age of 30.5 (20.6) years, were assessed. The most frequently affected joint...
Skeletal complications are a common occurrence in hemophilia. Regular consultations with orthopedic specialists, focusing on bleeding control and hepatitis prevention, are essential for reducing the i...
Hemophilia is characterized by a deficiency in coagulation factors VIII or IX. The general standard of care for severe hemophilia is frequent intravenous recombinant or plasma-derived factor replaceme...
To assess the impact of prophylaxis with rIX-FP, a fusion protein linking recombinant factor IX (FIX) with human albumin, on joint outcomes....
Joint outcomes were assessed in pediatric (<12 years) and adult/adolescent (≥12 years) patients receiving rIX-FP prophylaxis every 7, 10, or 14 days; patients (>18 years) well-controlled on a 14-day r...
For adult/adolescent (n = 63) and pediatric (n = 27) patients, median (Q1, Q3) annualized joint bleeding rate was 0.39 (0.00, 2.31), 0.80 (0.00, 2.85), 0.20 (0.00, 2.58), and 0.00 (0.00, 1.78) when tr...
Prophylaxis with rIX-FP produced low joint bleeding rates and provided excellent hemostatic efficacy in the treatment of joint bleeds. All target joints reported resolved with rIX-FP prophylaxis....